Zaiding Pharmaceutical announced that total revenue for the third quarter of 2026 was US$108.2 million, compared to US$116.1 million for the same period in 2025. Net product revenue for the third quarter of 2026 was US$107.6 million, compared to US$115.4 million for the same period in 2025. Net product revenue increased 2% month-on-month, mainly due to NZ and trimoxerin, and partly offset by a decline in revenue due to changes in the competitive landscape of the glioblastoma market for tumor electric field treatment. Net loss for the third quarter of 2026 was US$46.1 million, loss per common share attributable to common shareholders was US$0.04 (loss of $0.41), while net loss for the same period in 2025 was US$36 million, and loss per common share was US$0.03. The increase in net loss was mainly due to an inventory impairment of $13.6 million in 2026.

Zaiding Pharmaceutical announced that total revenue for the third quarter of 2026 was US$108.2 million, compared to US$116.1 million for the same period in 2025. Net product revenue for the third quarter of 2026 was US$107.6 million, compared to US$115.4 million for the same period in 2025. Net product revenue increased 2% month-on-month, mainly due to NZ and trimoxerin, and partly offset by a decline in revenue due to changes in the competitive landscape of the glioblastoma market for tumor electric field treatment. Net loss for the third quarter of 2026 was US$46.1 million, loss per common share attributable to common shareholders was US$0.04 (loss of $0.41), while net loss for the same period in 2025 was US$36 million, and loss per common share was US$0.03. The increase in net loss was mainly due to an inventory impairment of $13.6 million in 2026.